Only a clear strategy, intact timelines and a confident approach will ensure POET avoids the current fate of Rockley, which has had a disastrous slide since listing on the NAS.

There are, I believe other reasons for Rockley's slide.

There are certainly examples where stocks have uplisted to the nASDAQ and performed exceptionally well...even cash burning biotech's that list primarily to access the cash. But unless they are successful in their trials they usually fall hard. 

POET has a level of certainty that many new listings don't have.